LDS/Medical Tests/Propoxyphene, Serum

Propoxyphene, Serum

Propoxyphene is a mild opioid agonist that is structurally similar to methadone. Propoxyphene was removed from the US market in 2010 at the request of the FDA due to the cardiac toxicity associated with therapeutic doses. The FDA concluded that the safety risks outweigh the benefits of the drug. The typical route of administration was oral. Propoxyphene is rapidly metabolized to norpropoxyphene. Norpropoxyphene is further N-demethylated to dinorpropoxyphene, which is further metabolized to a cyclic dinorpropoxyphene. Several conjugates may also be formed. The half-life of propoxyphene is 8-24 hours.

Approximately 75% of a single oral dose is eliminated in the urine over 7 days. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.  

Common side effects: sedation, nausea, vomiting, dizziness, headache, miosis, blurred vision, constipation, urinary retention, and pruritis. Cardiac toxicity observed at therapeutic doses has been manifested by arrhythmias, prolonged PR interval, and widened QRS complex, in addition to hypotension, pulmonary edema, and circulatory collapse. Can be addictive and can lead to withdrawal symptoms in newborns of propoxyphene-using mothers. Overdose effects include cardiac arrest, coma, convulsions, circulatory and respiratory collapse, and possible death.  

Propoxyphene and metabolites can be detected in urine by a variety of analytical methods (see below), although availability of testing has declined since the drug was removed from the US market; both qualitative and quantitative tests may be available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Propoxyphene and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).

Alternative method: 

Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). Targeted assays can distinguish between propoxyphene and metabolites, although poor stability may contribute to false negative or contradictory results. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection.

Serum (SST) or plasma (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA:Biomedical Publications; 2002.
  • Levine B (ed). Miscellaneous Central Nervous System Depressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013:261-270.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011